Vitamin B6 injection composition capable of terminal sterilization and preparation method thereof

By controlling the pH value of vitamin B6 injection and adopting terminal sterilization technology, the problems of sterility and impurities are solved, the use of antibacterial agents is avoided, and the preparation of injections with high stability and safety is achieved, which meets the requirements of the pharmacopoeia.

CN118903002APending Publication Date: 2024-11-08NANJING ZHIHE MEDICINE TECH CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411288894.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-11-14
Filing Date
2024-09-14
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing vitamin B6 injection has low sterility guarantee level, excessive impurities, and hidden dangers of drug delivery in the terminal sterilization process. It also contains the antibacterial agent trichlorobutanol, which violates the requirements of the pharmacopoeia.

Method used

By strictly controlling the pH value of vitamin B6 injection within the range of 2.55 to 3.00, terminal sterilization process and metal ion chelating agents are used to clean it, avoid the use of antibacterial agents, and ensure the stability and safety of the product.

Benefits of technology

It achieves high sterility protection, low impurity content and low muscle irritation of vitamin B6 injection, meets the requirements of the pharmacopoeia, and improves the safety of drug administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005043907850000031
    Figure BDA0005043907850000031
  • Figure BDA0005043907850000101
    Figure BDA0005043907850000101
  • Figure BDA0005043907850000141
    Figure BDA0005043907850000141
Patent Text Reader

Abstract

The invention discloses an injection composition containing vitamin B6 and a dimer thereof and a preparation method of the injection composition. The composition is an aqueous solution for injection, wherein the mass volume percentage of vitamin B6 is 1.25-11% g / ml, the dimer 1 and the dimer 2 both do not exceed 0.15% of the amount of vitamin B6, the dimer 1 and the dimer 2 both do not exceed 0.2% of the amount of vitamin B6 in the period of validity, and the pH value of the aqueous solution is 2.55-3.00. The solution is good in thermal stability within the specific pH value range, and a terminal sterilization process can be adopted. The vitamin B6 injection prepared by the invention can tolerate a terminal sterilization process, does not contain a bacteriostatic agent, is low in solution color and stable, is low in irritation of an injection part, and overcomes the defects that a product in the market at present cannot have a higher sterile guarantee level, or is very strong in injection irritation or is relatively high in impurity content and potential safety hazards.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of pharmaceutical preparations, and specifically relates to a vitamin B6 injection which can withstand terminal sterilization, has better quality, better administration safety, and does not contain an antibacterial agent, and a preparation method thereof. Background Art

[0002] Vitamin B6 is a water-soluble vitamin. Currently, the available formulations include tablets and injections. Its chemical structure is as follows:

[0003] .

[0004] Vitamin B6 injection (Pyridoxine Hydrochloride Injection; VitaminB6Injection; Pyridoxine Hydrochloride Injection) was first launched on June 28, 1957 by Fuso Pharmaceutical Industry Co., Ltd. in Japan. In the United States, it was first launched on August 14, 1972 by FRESENIUS KABI USA LLC. The vitamin B6 injection launched by the company has the status of reference preparation in the United States and China. Its specifications are 1ml; 100mg, and the administration method is intravenous injection and intramuscular injection.

[0005] Vitamin B6 injection (specification 1ml: 100mg) is extremely sensitive to temperature, oxygen, pH value, etc. in neutral, alkaline or weakly acidic solutions, and is prone to produce impurities; this leads to problems of excessive impurities when preparing vitamin B6 injection using a terminal sterilization process with a higher level of aseptic assurance; at the same time, vitamin B6 is easily affected by metal ions in aqueous solution, causing the solution to turn yellow.

[0006] Currently, the impurity levels of the preparations on the market are reduced by lowering the concentration of the preparations (such as reducing the concentration of 1ml:100mg to 1ml:50mg or 25mg), but this method directly leads to inconsistency between the preparation specifications and the reference preparation, which is prone to confusion in dosage, and cannot pass the consistency evaluation; in addition, even if the concentration of the preparation is reduced, the impurity levels in the currently marketed preparations are close to the limit or even exceed the limit, which poses certain safety risks to the use of drugs by the public.

[0007] Patent CN111544377B, a vitamin B6 injection filled in a plastic ampoule and its preparation method, mentions a preparation method that can reduce the impurity level of the preparation. However, the inventors found during the research process that the method has problems such as poor reproducibility.

[0008] The reference preparations for vitamin B6 injection in my country (serial numbers 65-66) announced by the National Medical Products Administration in the "Catalogue of Reference Preparations for Chemical Generic Drugs (Sixty-fifth Batch)" in March 2023 are products of FRESENIUS KABI USA LLC in the United States. However, this reference preparation uses non-terminal sterilization, and the prescription contains the antibacterial agent chlorobutanol. Not only is the level of sterility protection low, but the drug is administered by intravenous and intramuscular injections. The addition of antibacterial agents will cause safety risks in clinical drug use; in the "Technical Guidance for the Research and Development of Drug Injections" issued in 2018, it is clearly stated that "Except as otherwise provided, intravenous, intrathecal, epidural and other injections shall not be added with antibacterial agents." It is also clearly stipulated in the General Rules for Preparations in the Appendix of the Chinese Pharmacopoeia under the Injection Item that "antibacterial agents shall not be added to injections for intravenous administration and intracisternal, epidural, and intraspinal administration." Summary of the invention

[0009] In view of this, the present invention provides a vitamin B6 injection that can withstand terminal sterilization, has better quality, better administration safety, and does not contain an antibacterial agent, and a preparation method thereof.

[0010] At present, there are great quality risks in the actual production of vitamin B6 injection, which leads to prominent safety risks of clinical products. In order to make the test results of listed products meet the requirements of statutory standards, some companies adopt sterilization processes with low aseptic assurance levels, but they do not know that the risk level of microbial risk is the highest for injections, which actually brings greater risks to patients. Other companies reduce the pH value of the product to increase its high temperature stability, reduce microbial risks and impurity levels, but if the pH value is reduced to the range of these companies' products, it will cause muscle damage or even necrosis at the injection site. This risk to patients is unacceptable. Therefore, the vitamin B6 injections currently on the market either cannot have a higher level of aseptic assurance or contain antibacterial agents, or are very irritating to injection, or have high impurity content and safety risks. These problems have not yet been satisfactorily resolved.

[0011] After in-depth research, the inventors unexpectedly found that by strictly controlling the pH value of vitamin B6 injection within a specific range, not only the heat stability of vitamin B6 is significantly improved and it can withstand terminal sterilization, the impurities can be controlled within the range specified by the guidelines, and the irritation of intramuscular injection can also meet the requirements.

[0012] Generally speaking, the degradation pathways and degradation products (impurities and their contents) of compounds under different acid-base environments, different temperature environments, etc. are different. The inventors have studied and determined for the first time the structural formulas of dimer 1 and dimer 2 produced by vitamin B6 in the production of vitamin B6 injection according to the prescription process of the present invention, and confirmed them as common impurities through structure-activity relationship analysis and structural safety assessment. By studying the inherent laws of the changes of the two impurities, they have invented a preparation method that can prepare a highly stable vitamin B6 injection and ensure that it does not exceed the limits specified in the guidelines during its shelf life.

[0013]

[0014] It is particularly important that the vitamin B6 injection is administered intravenously and intramuscularly. During the research, the inventors found that a lower pH value is likely to cause irritation or even muscle damage when administered intramuscularly, and unexpectedly found that there is a critical pH value for the thermal stability and irritation of the product. Within a specific pH range, it can tolerate terminal sterilization, control impurities within a lower range, ensure low muscle irritation, and eliminate the use of antibacterial agents in the prescription.

[0015] According to the composition of vitamin B6 injection and its preparation method of the present invention, a terminal sterilization process is adopted, and the bacteriostatic agent chlorobutanol used in the reference preparation can be exempted from the prescription. The relevant embodiment of the present invention shows that the chlorobutanol in the prescription amount of the reference preparation only plays the role of a bacteriostatic agent in the prescription, and has no effect of relieving pain and reducing muscle irritation pain. Therefore, another advantage of the present invention is that the product does not contain the bacteriostatic agent chlorobutanol, which is more in line with the requirements of the general rules for injection preparations in the appendix of the Chinese Pharmacopoeia, and the clinical medication is safer.

[0016] In summary, the inventors have invented a prescription composition and production process of vitamin B6 injection through systematic research and comprehensive consideration of factors such as the sterility assurance level of the preparation, the level of impurity control, the control of solution color change and the safety of administration. They have successfully solved the problems of injection sterilization process selection, preparation impurity control, and administration irritation, and obtained a vitamin B6 injection that does not contain antibacterial agents and a preparation method thereof, which can withstand terminal sterilization, has better quality and is safer for clinical use.

[0017] The present invention provides a vitamin B6 injection that can withstand terminal sterilization and does not contain an antibacterial agent. The vitamin B6 injection contains 1.25% to 11% g / ml of vitamin B6 by mass volume percentage, and the content of dimer 1 and dimer 2 does not exceed 0.15% of the amount of vitamin B6, and does not exceed 0.2% of the vitamin B6 content during the validity period. The pH value of the injection is between 2.55 and 3.00, preferably 2.58 to 2.85;

[0018] In some embodiments, the vitamin B6 injection provided by the present invention further includes a pH adjuster, and the pH adjuster is one or a combination of sodium hydroxide, disodium hydrogen phosphate, and sodium bicarbonate; optionally, the mass volume percentage of the pH adjuster in the injection is 0.5% to 5% g / ml.

[0019] On the other hand, the present invention provides a method for preparing the above-mentioned vitamin B6 injection, the preparation method comprising: cleaning the stainless steel pipeline with a metal ion chelator solution before preparation, sterilizing it with a terminal sterilization process, the sterilization temperature is: 110-122°C, the sterilization time is 8-48 minutes, and the F0 value is 8-25.

[0020] In some embodiments, the method for preparing the vitamin B6 injection comprises the following steps:

[0021] (1) Use a certain concentration of metal ion chelating agent solution to passivate and clean the liquid distribution system pipeline to remove metal ions on the surface;

[0022] (2) adding a portion of water for injection into the liquid preparation system, controlling the dissolved oxygen to below 3.0 mg / L, and adding the raw materials for dissolution;

[0023] (3) After the dissolution is completed, a certain concentration of pH adjuster is added to adjust the pH value to 2.58-2.85 and the volume is fixed;

[0024] (4) sterilizing the above solution, controlling the residual oxygen in the headspace to below 3.0%, filling and sealing, and terminal sterilization to obtain a finished product.

[0025] In some embodiments, the present invention provides a method for preparing a vitamin B6 injection, wherein the concentration of the metal ion chelator is 0.05% to 5% g / ml by mass volume; and / or the passivation cleaning time is 0.5 to 2 hours; and / or the cleaning temperature is 20 to 50°C.

[0026] In some embodiments, the present invention provides a method for preparing a vitamin B6 injection, wherein an overkill method (sterilization at 121° C. for 12 min) is used in a terminal sterilization process.

[0027] On the other hand, the present invention provides a vitamin B6 injection prepared by the above-mentioned preparation method.

[0028] The beneficial effects of adopting the technical solution of the present invention are:

[0029] (1) It enables vitamin B6 injection to withstand terminal sterilization process, thus ensuring the level of sterility to the greatest extent.

[0030] (2) The dimer level of the samples prepared by this process is stable and controllable, and the color change of the preparation is small during the stability study. It is a preparation process of vitamin B6 injection with better quality.

[0031] (3) The VB6 injection prepared by this process has lower irritation and higher safety when administered intramuscularly. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.

[0033] Figure 1 The mass spectrum of dimer 1 provided in Example 6 of the present invention;

[0034] Figure 2 This is the hydrogen spectrum of dimer 1 provided in Example 6 of the present invention;

[0035] Figure 3 The carbon spectrum of dimer 1 provided in Example 6 of the present invention;

[0036] Figure 4 This is the hydrogen spectrum of dimer 2 provided in Example 6 of the present invention;

[0037] Figure 5 The carbon spectrum of dimer 2 provided in Example 6 of the present invention;

[0038] Figure 6 A comparison diagram of changes in the muscle surface of Comparative Example 1 and Comparative Example 4 provided in Experimental Example 3 of the present invention;

[0039] Figure 7 The histopathological experimental diagram of Example 1 provided in Experimental Example 3 of the present invention;

[0040] Figure 8 The histopathological experimental diagram of Example 2 provided in Experimental Example 3 of the present invention;

[0041] Fig. 9 The histopathological experimental diagram of Example 3 provided in Experimental Example 3 of the present invention;

[0042] Fig.10 This is a histopathological experimental diagram of Comparative Example 4 provided for Experimental Example 3 of the present invention. DETAILED DESCRIPTION

[0043] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with embodiment. Unless otherwise defined, all professional terms used hereinafter are the same as those skilled in the art generally understand. The professional terms used herein are only for the purpose of describing specific embodiments and are not intended to limit the scope of protection of the present invention. Unless otherwise specified, the various reagents and raw materials used in the present invention are all commodities that can be purchased from the market or products that can be prepared by known methods.

[0044] In order to better illustrate the present invention, further examples are given below.

[0045] Example 1

[0046] Prescription composition Dosage Vitamin B6 100g 4% NaOH solution Adjust pH to 2.58 Add water for injection to 1000ml

[0047] Preparation process:

[0048] Use 0.1% disodium edetate solution to clean and passivate the liquid distribution system pipeline (cleaning time: 1h, cleaning temperature: 20-30°C);

[0049] 80% of water for injection is added to the liquid preparation system, and the dissolved oxygen is controlled to be below 3.0 mg / L, and the raw materials are added for dissolution.

[0050] After the dissolution is completed, add an appropriate amount of 4% sodium hydroxide to adjust the pH value of the solution to 2.58, and then make up the volume after the adjustment is completed.

[0051] The above-mentioned drug solution is sterilized and filtered, and nitrogen is filled to control the residual oxygen in the headspace to be less than 3%, and the solution is filled and sealed at 1 ml / vial.

[0052] The terminal sterilization process is adopted, and the parameters of 121°C / 15min are used for sterilization to obtain the finished product.

[0053] Example 2

[0054] Prescription composition Dosage Vitamin B6 100g 4% NaOH solution Adjust pH to 2.85 Add water for injection to 1000ml

[0055] Preparation process:

[0056] Use 0.1% disodium edetate solution to clean and passivate the liquid distribution system pipeline (cleaning time: 1h, cleaning temperature: 20-30°C);

[0057] Add 80% of water for injection into the liquid preparation system and control the concentration below 3 mg / L, then add the raw materials for dissolution.

[0058] After the dissolution is completed, add an appropriate amount of 4% sodium hydroxide to adjust the pH value of the solution to 2.85, and then make up the volume after the adjustment is completed.

[0059] The above-mentioned drug solution is sterilized and filtered, and nitrogen is filled to control the residual oxygen in the headspace to be less than 3%, and the solution is filled and sealed at 1 ml / vial.

[0060] The terminal sterilization process is adopted, and the parameters of 121°C / 15min are used for sterilization to obtain the finished product.

[0061] Example 3

[0062] Prescription composition Dosage Vitamin B6 25g 4% NaOH solution Adjust pH to 2.67 Add water for injection to 1000ml

[0063] Preparation process:

[0064] Use 0.1% disodium edetate solution to clean and passivate the liquid distribution system pipeline (cleaning time: 1h, cleaning temperature: 20-30°C);

[0065] 80% of water for injection is added to the liquid preparation system and the concentration is controlled below 3 mg / L, and the raw materials are added to dissolve.

[0066] After the dissolution was completed, an appropriate amount of 4% sodium hydroxide was added to adjust the pH value of the solution to 2.67, and the volume was fixed after the adjustment was completed.

[0067] The above-mentioned drug solution is sterilized and filtered, and nitrogen is filled to control the residual oxygen in the headspace to be less than 3%, and the solution is filled and sealed at 1 ml / vial.

[0068] The terminal sterilization process is adopted, and the parameters of 121°C / 15min are used for sterilization to obtain the finished product.

[0069] Example 4

[0070] Prescription composition Dosage Vitamin B6 100g 4% NaOH solution Adjust pH to 2.72 Add water for injection to 1000ml

[0071] Preparation process:

[0072] Use 0.1% disodium edetate solution to clean and passivate the liquid distribution system pipeline (cleaning time: 1h, cleaning temperature: 20-30°C);

[0073] Add 80% of water for injection into the liquid preparation system and control the concentration below 3 mg / L, then add the raw materials for dissolution.

[0074] After the dissolution was completed, an appropriate amount of 4% sodium hydroxide was added to adjust the pH value of the solution to 2.74, and the volume was fixed after the adjustment was completed.

[0075] The above-mentioned drug solution is sterilized and filtered, and nitrogen is filled to control the residual oxygen in the headspace to be less than 3%, and the solution is filled and sealed at 1 ml / vial.

[0076] The terminal sterilization process is adopted, and the parameters of 121°C / 8min are used for sterilization to obtain the finished product.

[0077] Example 5

[0078] Prescription composition Dosage Vitamin B6 100g 4% NaOH solution Adjust pH to 2.74 Add water for injection to 1000ml

[0079] Preparation process:

[0080] Use 0.1% disodium edetate solution to clean and passivate the liquid distribution system pipeline (cleaning time: 1h, cleaning temperature: 20-30°C);

[0081] Add 80% of water for injection into the liquid preparation system and control the concentration below 3 mg / L, then add the raw materials for dissolution.

[0082] After the dissolution was completed, an appropriate amount of 4% sodium hydroxide was added to adjust the pH value of the solution to 2.74, and the volume was fixed after the adjustment was completed.

[0083] The above-mentioned drug solution is sterilized and filtered, and nitrogen is filled to control the residual oxygen in the headspace to be less than 3%, and the solution is filled and sealed at 1 ml / vial.

[0084] The terminal sterilization process is adopted, and the parameters of 115℃ / 45min are used for sterilization to obtain the finished product.

[0085] Example 6

[0086] Prescription composition Dosage Vitamin B6 100g 4% NaOH solution Adjust pH to 3.00 Add water for injection to 1000ml

[0087] Preparation process:

[0088] Use 0.1% disodium edetate solution to clean and passivate the liquid distribution system pipeline (cleaning time: 1h, cleaning temperature: 20-30°C);

[0089] Add 80% of water for injection into the liquid preparation system and control the concentration below 3 mg / L, then add the raw materials for dissolution.

[0090] After the dissolution is completed, add an appropriate amount of 4% sodium hydroxide to adjust the pH value of the solution to 3.00, and then make up the volume after the adjustment is completed.

[0091] The above-mentioned drug solution is sterilized and filtered, and nitrogen is filled to control the residual oxygen in the headspace to be less than 3%, and the solution is filled and sealed at 1 ml / vial.

[0092] The terminal sterilization process is adopted, and the parameters of 121°C / 8min are used for sterilization to obtain the finished product.

[0093] Example 7

[0094] Structural confirmation of dimers 1 and 2:

[0095] Preparation of dimer: Dissolve the raw material in purified water, adjust the pH to 5.0 with sodium hydroxide, heat destroy at 105℃ / 48h, extract, concentrate by rotary evaporation at 35℃ water bath, and freeze-dry to obtain dimer 1 and dimer 2.

[0096] Impurity structure confirmation: The structure of the dimer was determined by carbon spectrum, hydrogen spectrum, mass spectrum, nuclear magnetic resonance and purity analysis. The mass spectrum of dimer 1 is shown in Figure 1 , the hydrogen spectrum of dimer 1 is shown in Figure 2 , the carbon spectrum of dimer 1 is shown in Figure 3 , the hydrogen spectrum of dimer 2 is shown in Figure 4 , dimer 2 carbon spectrum see Figure 5 .

[0097]

[0098] Dimer 1: MS: [M+H]+=321.2, [MH]-=319.6. 1H NMR (400 MHz, DMSO) δ11.86 (s, 1H), 9.42 (s, 1H), 7.86 (s, 1H), 5.72 (s, 1H), 5.60 (s, 1H), 5.35 (s, 1H), 4.79 (s, 2H), 4.76 (s, 2H), 4.60 (s, 2H), 4.16 (s, 2H), 2.34 (s, 3H), 2.32 (s, 3H). 13C NMR (101MHz, DMSO) δ151.21,149.13,148.21,147.10,144.83,140.02,135.64,134.37,133.17,131.78,60.12,56.88,56.67,30.18,19.95,19.17.

[0099] Dimer 2: MS: [M+H]+=321.2, [MH]-=319.6. 1H NMR (400 MHz, DMSO) δ8.04 (s, 1H), 6.99 (s, 1H), 5.51 (s, 2H), 4.57 (s, 2H), 4.48 (s, 2H), 4.31 (s, 2H), 2.56 (s, 3H), 2.41 (s, 3H). 13C NMR (101MHz, DMSO) δ166.08,147.20,143.27,139.39,137.24,135.10,134.96,133.56,127.08,119.82,59.41,59.19,58.38,56.99,19.76,12.71.

[0100] Comparative Example 1

[0101] Prescription composition Dosage Vitamin B6 100g 4% NaOH solution Adjust pH to 2.50 Add water for injection to 1000ml

[0102] Preparation process:

[0103] Use 0.1% disodium edetate solution to clean and passivate the liquid distribution system pipeline (cleaning time: 1h, cleaning temperature: 20-30°C);

[0104] Add 80% of water for injection into the liquid preparation system and control the concentration below 3 mg / L, then add the raw materials for dissolution.

[0105] After the dissolution is completed, add an appropriate amount of 4% sodium hydroxide to adjust the pH value of the solution to 2.50, and then make up the volume after the adjustment is completed.

[0106] The above-mentioned drug solution is sterilized and filtered, and nitrogen is filled to control the residual oxygen in the headspace to be less than 3%, and the solution is filled and sealed at 1 ml / vial.

[0107] The terminal sterilization process is adopted, and the parameters of 121°C / 15min are used for sterilization to obtain the finished product.

[0108] Comparative Example 2

[0109] Prescription composition Dosage Vitamin B6 100g 4% NaOH solution Adjust pH to 3.20 Add water for injection to 1000ml

[0110] Preparation process:

[0111] Use 0.1% disodium edetate solution to clean and passivate the liquid distribution system pipeline (cleaning time: 1h, cleaning temperature: 20-30°C);

[0112] 80% of water for injection is added to the liquid preparation system and the concentration is controlled below 3 mg / L, and the raw materials are added to dissolve.

[0113] After the dissolution is completed, add an appropriate amount of 4% sodium hydroxide to adjust the pH value of the solution to 3.20, and then make up the volume after the adjustment is completed.

[0114] The above-mentioned drug solution is sterilized and filtered, and nitrogen is filled to control the residual oxygen in the headspace to be less than 3%, and the solution is filled and sealed at 1 ml / vial.

[0115] The terminal sterilization process is adopted, and the parameters of 121°C / 8min are used for sterilization to obtain the finished product.

[0116] Comparative Example 3

[0117] Prescription composition Dosage Vitamin B6 100g 4% NaOH solution Adjust pH to 2.64 Add water for injection to 1000ml

[0118] Preparation process:

[0119] Add 80% of water for injection into the liquid preparation system and control the concentration below 3 mg / L, then add the raw materials for dissolution.

[0120] After the dissolution is completed, add an appropriate amount of 4% sodium hydroxide to adjust the pH value of the solution to 2.64, and then make up the volume after the adjustment is completed.

[0121] The above-mentioned drug solution is sterilized and filtered, and nitrogen is filled to control the residual oxygen in the headspace to be less than 3%, and the solution is filled and sealed at 1 ml / vial.

[0122] The terminal sterilization process is adopted, and the parameters of 121°C / 15min are used for sterilization to obtain the finished product.

[0123] Comparative Example 4

[0124] Reference preparation:

[0125] Generic Name: Vitamin B6 Injection

[0126] English Name: Pyridoxine Hydrochloride Injection

[0127] Licensee: FRESENIUS KABI USA LLC

[0128] Specification: 1ml: 100mg

[0129] Batch number: 6032156

[0130] The inventors conducted a systematic stability study (including dimer change and color change) and administration safety study on each preparation sample in the above-mentioned embodiments and comparative examples.

[0131] Experimental Example 1

[0132] Dimer detection method (HPLC):

[0133] Chromatographic conditions:

[0134] Chromatographic column: Octadecylsilane bonded silica gel as filler (Thermo Acclaim 120C18, 4.6 mm × 250 mm, 5 μm or a chromatographic column with equivalent performance);

[0135] Mobile phase: 0.01 mol / L sodium pentane sulfonate solution (adjust pH to 3.0 with glacial acetic acid) as mobile phase A, methanol as mobile phase B; gradient elution according to Table 1 below;

[0136] Flow rate: 1.0ml / min;

[0137] Column temperature: 30°C;

[0138] Detection wavelength: 291nm;

[0139] Injection volume: 10 μl.

[0140] Table 1 Gradient elution program

[0141] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 90 10 5 90 10 25 80 20 50 45 55 60 45 55 61 90 10 75 90 10

[0142] Experimental Example 2

[0143] Test process: Test Example 1, Example 2, Example 3, Example 4, Example 5, Example 6, Comparative Example 1, Comparative Example 2, Comparative Example 3, Comparative Example 4, samples before sterilization, samples after sterilization, and place the sterilized samples under long-term conditions (25°C ± 2 ℃ , 60%RH±5%RH)), samples were taken at 3 months and 6 months to test the dimer content and color change. The test results are as follows:

[0144] Table 2 Results of dimer content detection in long-term experiments

[0145]

[0146]

[0147]

[0148] The test results show that:

[0149] In Example 1, Example 2, Example 3, Example 4, Example 5, and Example 6 (after washing with disodium edetate solution, adjusting the pH value to 2.58-3.00, and sterilizing with a terminal sterilization process of 115° C.-121° C., 45 min-8 min sterilization parameters), the dimer content and color change of the samples after long-term testing for 3 months and 6 months were within the acceptable range, and based on the growth trend, it was inferred that the samples were within the limit of 0.2% within the validity period (24 months).

[0150] In comparative example 1, the pH value was 2.50, and the dimer content and color change in the long term of 3 months and 6 months were also within the acceptable range.

[0151] In comparative example 2, the pH value is 3.20. Based on the long-term 6-month impurity growth trend, it is inferred that the impurities will exceed the limit within the validity period (24 months).

[0152] Comparative Example 3, where edetate disodium solution was not used for rinsing, based on the color growth trend over a long period of 6 months, it was inferred that the color would exceed the limit within the effective period (24 months).

[0153] (Acceptable standard: dimer content: ≤0.2%; color ≤ yellow No. 4)

[0154] Experimental Example 3 Drug administration safety study

[0155] Study Name: Muscle Stimulation Study

[0156] Study purpose: To evaluate the stimulatory effect of the test drug on rabbit muscles by intramuscular injection and to provide a reference for the safe clinical use of the drug.

[0157] Research animals: Japanese white rabbits of common grade, weighing 2.0-2.5 kg, male, fed with complete nutritional feed. Research instruments and consumables: No. 4 needle 1mL syringe, electronic balance, etc.

[0158] Research Methodology:

[0159] (1) Dosage / concentration / time of administration

[0160] Table 3 Administration

[0161]

[0162] Note: * indicates that the animal weight is within the range of 2.0-2.5 kg, and the dosage volume is not calculated;

[0163] When grouping, the animals were grouped evenly according to their weight.

[0164] (2) Method of administration

[0165] A single concentration of drug was set for each group, with 2 rabbits in each group. The left and right sides of the same body were compared by self-comparison method, and normal saline was used as the control group. The drug was administered continuously for 3 days, once a day. The hair was prepared before injection and disinfected with alcohol cotton balls. The drug was injected into the quadriceps femoris on both sides. The test drug was injected on one side, and normal saline was injected on the other side as the negative control group. The needle was inserted vertically for 1 cm, and the injection was slow (1 mL / 10 s). The needle was quickly removed after the injection without massaging the injection site. Local reactions such as congestion, redness, and swelling were observed before each administration and 24 hours and 48 hours after the last administration.

[0166] 48 hours after administration, the animals were autopsied to observe the local irritation reaction at the injection site, the corresponding reaction level was calculated according to Table 1, and local tissue pathology examination was performed and pathological photos were provided.

[0167] (3) Recovery period

[0168] There is no recovery period in this trial.

[0169] (4)Acquisition of materials

[0170] The animals were killed after anesthesia. The skin was cut from the knee joint to the groin on the front of the thigh of the experimental animal. After the fascia of the quadriceps femoris was cut, the quadriceps femoris was bluntly separated, taken out, and observed with the naked eye. The longitudinal section and cross section were taken at the injection site for histopathological examination. The results of histopathological examination are mainly used to determine the nature and extent of the lesion, rather than to determine the scope of the lesion. Therefore, there is no need to take samples extensively. Only two pieces of tissue (one each on the test side and the control side) need to be taken from the most significant part of the lesion observed with the naked eye, and four pathologies are required for each rabbit.

[0171] Result evaluation method:

[0172] (1) Visual observation

[0173] First, record the changes on the muscle surface, then observe the longitudinal section along the muscle shape. If there is any abnormality, record the color and long and short diameters of the lesion. If there is no significant lesion, make a longitudinal cut at the needle insertion site and observe. Calculate the total muscle irritation reaction level according to Table 4, calculate the average value, and determine the stimulation level according to Table 5. If the difference between the highest and lowest reaction levels of each quadriceps muscle is greater than 2, another animal should be retested.

[0174] Table 4 Classification criteria for muscle stimulation response

[0175] Stimulus Response Reaction level No significant changes 0 Mild congestion, less than 0.5 × 1.0 cm 1 Moderate congestion, with an area of ​​0.5 × 1.0 cm or more 2 Severe congestion with muscle degeneration 3 Necrosis and brown degeneration 4 Extensive necrosis 5

[0176] Table 5 Average scores and grades

[0177] Average score grade 0.0~0.4 none 0.5~1.4 slight 1.5~2.4 Mild 2.5~3.4 Moderate 3.5~4.4 Severe 4.5 and above serious

[0178] (2) Histopathological evaluation

[0179] Describe the pathological changes of the inspection site in detail, and analyze and judge the muscle irritation. Mainly observe whether the muscle fibers have degeneration, necrosis, dissolution, inflammatory cell infiltration, bleeding and other lesions, as well as the distribution range of each lesion. Whether there is interstitial edema, widening, inflammatory cell infiltration, bleeding and other lesions.

[0180] (3) Result determination

[0181] The muscle irritation of the test substance is judged comprehensively based on the results of naked eye observation and histopathological examination, and the results of muscle histopathological diagnosis are used as the main basis to determine whether the test drug has muscle irritation.

[0182] Test results:

[0183] (1) Visual observation results

[0184] The autopsy results showed that the muscle of Comparative Example 1 (pH 2.50) had brown lesions, and the irritation reached level 4, which was unacceptable; the changes in the muscle surface of Comparative Example 1 and Comparative Example 4 were as follows: Figure 6 The muscles of Example 1 (pH 2.58), Example 2 (pH 2.85), Example 3 (2.64), and Comparative Example 4 (pH 3.0) were slightly congested, which was within an acceptable range.

[0185] Table 6 Rabbit muscle irritation observation record

[0186]

[0187]

[0188] Table 7 Rabbit muscle irritation autopsy observation record score table

[0189]

[0190] (2) Histopathological evaluation

[0191] Samples were collected from the left and right muscle injection sites of rabbits in each group, and then embedded, fixed, sectioned and HE-stained for histopathological analysis.

[0192] Example 1 (see Figure 7 ) No abnormal pathological changes were found in the muscle tissues of rabbit No. 1 on both sides. A small number of inflammatory cells appeared on the control side of rabbit No. 2 itself. A small number of inflammatory cells cannot be judged as abnormal muscle irritation, which may be related to the drug administration operation; the muscle cell structure on the drug administration side was unclear, inflammatory cells were seen locally, and a small amount of powder staining appeared on the muscle cells, which is a precursor to muscle necrosis.

[0193] Example 2 (see Figure 8 ) No abnormal pathological changes were found in the muscle tissues of rabbit No. 3 on both sides. A large number of inflammatory cells were infiltrated in the muscle tissues of rabbit No. 4 on the drug-treated side, and no abnormal pathological changes were found on the control side.

[0194] Example 3 (see Fig. 9 There was no abnormality in the muscle pathology of rabbit No. 5 on both sides. A large number of inflammatory cells infiltrated the muscle tissue of rabbit No. 6 on the control side and the drug-treated side.

[0195] Comparative Example 4 (see Fig.10 ) The muscle pathology of rabbit No. 9 on both sides showed no abnormality. The muscle anatomy of rabbit No. 10 on the administration side showed a small amount of inflammatory cell infiltration.

[0196] (3) Experimental conclusion

[0197] Example 1, according to the irritation reaction score, was judged to be slightly irritating during the administration period. Histopathological results showed that after administration, the muscle cells on the administration side of the rabbits were pink-stained, and the comprehensive local observation and pathological observation judged that it was slightly irritating.

[0198] Example 2: According to the irritation reaction score, the drug administration period was judged to be mildly irritating. Histopathological results showed that a large number of inflammatory cells infiltrated the second administration side, indicating mild muscle irritation.

[0199] Example 3, according to the irritation reaction score, it was judged to be slightly irritating during the administration period. Histopathological results showed that after administration, a large number of inflammatory cells infiltrated the muscles of the rabbits, and the comprehensive local observation and pathological observation judged that it was slightly irritating.

[0200] In Comparative Example 1, based on the observation of muscle irritation, muscle necrosis and brown degeneration occurred; the irritation was unacceptable.

[0201] Comparative Example 4 was judged to be non-irritating during the administration period according to the irritation reaction score. Histopathological results showed that after administration, a small amount of inflammatory cell infiltration occurred on the administration side of the rabbit, and the comprehensive local observation and pathological observation judged that it was slightly irritating.

[0202] Experimental Example 4 Analgesic Experimental Study of Chlorobutanol

[0203] Chlorobutanol is a pharmaceutical excipient with antibacterial effects. It is often used as an antibacterial agent in injections and eye drops. In addition, chlorobutanol also has certain sedative and local analgesic effects. Vitamin B6 injection is a low pH preparation, and there is a certain pain when administering it. To further confirm whether adding chlorobutanol to the prescription has an analgesic effect, samples containing / not containing chlorobutanol were prepared; the acetic acid writhing test model was used to conduct an analgesic test, and compared with the negative control group, it was studied whether the samples containing chlorobutanol had an analgesic effect.

[0204] (1) Experimental plan

[0205] Table 8 Test plan

[0206]

[0207] (2) Research results:

[0208] Table 9 analgesia test results

[0209]

[0210]

[0211] Note: Meaning of the number, such as "1F01" 1 refers to the first group, F refers to female, M refers to male, and 01 refers to the first animal.

[0212] (3) Research conclusions:

[0213] The results of the study showed that the chlorobutanol in the prescription had no analgesic effect.

[0214] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A vitamin B6 injection composition, Features: (1) The content of vitamin B6 is 1.25% to 11% (g / ml) by mass volume percentage, and the content of dimer 1 and dimer 2 does not exceed 0.15% of the vitamin B6 content, and does not exceed 0.2% of the vitamin B6 content during the validity period; (2) It does not contain any antibacterial agent; (3) The pH value of the injection is between 2.55 and 3.00, preferably 2.58 to 2.85: (4) The injection has good thermal stability and can withstand terminal sterilization process. The structural formulas of dimer 1 and dimer 2 are as follows:

2. The injection according to claim 1, It is characterized in that The invention also includes a pH regulator, which is one or a combination of sodium hydroxide, disodium hydrogen phosphate or sodium bicarbonate.

3. The injection according to any one of claims 1 to 2, It is characterized in that The chromatographic column of the dimer HPLC determination method uses octadecylsilane bonded silica gel as a filler, the mobile phase contains ion pair reagents sodium pentane sulfonate, water and methanol, gradient elution, and detection by an ultraviolet detector at 291nm; the content of dimer 1 and dimer 2 can be either a percentage equivalent to the mass of vitamin B6, or a measurement value according to the main component self-control method or peak area normalization method of this method.

4. A method for preparing the vitamin B6 injection according to any one of claims 1 to 3, It is characterized in that The terminal sterilization process is used for sterilization, the sterilization temperature is 110-122°C, the sterilization time is 8-48 minutes, and the F0 value is 8-25.

5. The preparation method according to claim 4, It is characterized in that The following steps are involved: (1) Before preparing the injection solution, use a metal ion chelating agent solution such as disodium EDTA or sodium calcium EDTA to clean and passivate the liquid preparation system and stainless steel pipelines; (2) adding a portion of the water for injection into the liquid preparation system, controlling the dissolved oxygen to meet the requirement, and then adding the raw materials for dissolution; (3) After the dissolution is completed, a pH adjuster is added to adjust the pH of the solution to 2.58-2.85 and the volume is fixed; (4) Filtration, nitrogen filling, sealing, and terminal sterilization to obtain the finished product.

6. The preparation method according to claim 5, It is characterized in that The metal ion chelating agent is disodium edetate or sodium calcium edetate or a combination thereof, the mass volume percentage of the solution concentration is 0.05% to 5%, the cleaning time is 0.5 to 2 hours, and the cleaning temperature is 20 to 50°C.

7. The preparation method according to claim 4 or 5, It is characterized in that The sterilization method adopted is hot pressure sterilization. When the sterilization temperature is 115±3℃, the sterilization time is 30 to 48 minutes; or when the sterilization temperature is 121±3℃, the sterilization time is 8 to 13 minutes; or when the sterilization temperature is 121±3℃, the sterilization time is 14 to 16 minutes.

8. The method for preparing the injection according to claim 5, It is characterized in that The dissolved oxygen value must be controlled below 3.0 mg / L during the liquid preparation process; or / and nitrogen must be filled during the filling process, and the residual oxygen value in the inner packaging container space must be controlled below 3.0%.

Citation Information

Cited By

  • High-stability vitamin B6 injection

    CN122499105A